Compounds > 1-arabinofuranosylcytosine-5--stearylphosphate

1-arabinofuranosylcytosine-5--stearylphosphate and Liver-Neoplasms

1-arabinofuranosylcytosine-5--stearylphosphate has been researched along with Liver-Neoplasms* in 2 studies

Trials

2 trial(s) available for 1-arabinofuranosylcytosine-5--stearylphosphate and Liver-Neoplasms

Article	Year
[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:12 Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki University Hospital. They were treated with YNK-01, a prodrug of cytarabine for oral administration. YNK-01 was given for 2 weeks and repeated every 4 weeks for as long as possible. There were 13 patients with NC, 10 with PD, and no PR. Among NC cases, 5 patients were maintained with NC for longer than 6 months. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc), but no severe side effects over Grade 3 were observed. Topics: Administration, Oral; Aged; Anemia; Anorexia; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Thrombocytopenia	1998
The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 6 Thirty-two patients with hepatocellular carcinoma (HCC) were treated with YNK-01, a prodrug of cytarabine for oral administration. A dose of 200 mg/d of YNK-01 was administered to 17 cases and 300 mg/d to 15 cases. One course was 2 weeks in duration, and this was repeated every 4 weeks for as long as the patients were able to tolerate it. There were five partial responses (15%) and 13 patients with no change (41%). A higher partial response rate was observed in the 300 mg/d group (27%) compared with the 200 mg/d group (6%). The average durations of partial response and no change were approximately 4 and 3 months, respectively. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc). These results suggest that YNK-01 is a potentially useful oral agent for chemotherapy of hepatocellular carcinoma. Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prodrugs; Tomography, X-Ray Computed	1997

Article

Year

[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:12

Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki University Hospital. They were treated with YNK-01, a prodrug of cytarabine for oral administration. YNK-01 was given for 2 weeks and repeated every 4 weeks for as long as possible. There were 13 patients with NC, 10 with PD, and no PR. Among NC cases, 5 patients were maintained with NC for longer than 6 months. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc), but no severe side effects over Grade 3 were observed.

Topics: Administration, Oral; Aged; Anemia; Anorexia; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Thrombocytopenia

1998

The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma.

Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 6

Thirty-two patients with hepatocellular carcinoma (HCC) were treated with YNK-01, a prodrug of cytarabine for oral administration. A dose of 200 mg/d of YNK-01 was administered to 17 cases and 300 mg/d to 15 cases. One course was 2 weeks in duration, and this was repeated every 4 weeks for as long as the patients were able to tolerate it. There were five partial responses (15%) and 13 patients with no change (41%). A higher partial response rate was observed in the 300 mg/d group (27%) compared with the 200 mg/d group (6%). The average durations of partial response and no change were approximately 4 and 3 months, respectively. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc). These results suggest that YNK-01 is a potentially useful oral agent for chemotherapy of hepatocellular carcinoma.

Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prodrugs; Tomography, X-Ray Computed

1997